From Kinetics and Cellular Cooperations to Cancer Immunotherapies

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Mar 26

PMID 27014912

Citations 1

Authors

Alain Trautmann

Affiliations

Soon will be listed here.

Abstract

In this review will be underlined two simple ideas of potential interest for the design of cancer immunotherapies. One concerns the importance of kinetics, with the key notion that a single cause may trigger two opposite effects with different kinetics. The importance of this phenomenon will be underlined in neurobiology, transcription networks and the immune system. The second idea is that efficient immune responses have been selected against pathogens, throughout evolution. They are never due to a single cell type, but always require multiple, complex cellular cooperations. One cannot recognize this fact and persist in the presently dominant T-cell centered view of cancer immunotherapies. Suggestions will be made to incorporate these simple ideas for improving these therapies.

Citing Articles

The discontinuity theory of immunity.

Pradeu T, Vivier E Sci Immunol. 2017; 1(1).

PMID: 28239677 PMC: 5321532. DOI: 10.1126/sciimmunol.aag0479.

References

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Morgan R, Chinnasamy N, Abate-Daga D, Gros A, Robbins P, Zheng Z . Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013; 36(2):133-51. PMC: 3581823. DOI: 10.1097/CJI.0b013e3182829903. View

Rajani K, Parrish C, Kottke T, Thompson J, Zaidi S, Ilett L . Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol Ther. 2015; 24(1):166-74. PMC: 4754544. DOI: 10.1038/mt.2015.156. View

Rosenberg S, Zhai Y, Yang J, Schwartzentruber D, Hwu P, Marincola F . Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst. 1998; 90(24):1894-900. PMC: 2249697. DOI: 10.1093/jnci/90.24.1894. View

Isogawa M, Furuichi Y, Chisari F . Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. Immunity. 2005; 23(1):53-63. DOI: 10.1016/j.immuni.2005.05.005. View

Litman G, Anderson M, RAST J . Evolution of antigen binding receptors. Annu Rev Immunol. 1999; 17:109-47. DOI: 10.1146/annurev.immunol.17.1.109. View

Tarhini A, Gogas H, Kirkwood J . IFN-α in the treatment of melanoma. J Immunol. 2012; 189(8):3789-93. PMC: 4420629. DOI: 10.4049/jimmunol.1290060. View

Goldszmid R, Trinchieri G . The price of immunity. Nat Immunol. 2012; 13(10):932-8. DOI: 10.1038/ni.2422. View

Zhao Z, Granucci F, Yeh L, Schaffer P, CANTOR H . Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science. 1998; 279(5355):1344-7. DOI: 10.1126/science.279.5355.1344. View

10.

Kakarla S, Gottschalk S . CAR T cells for solid tumors: armed and ready to go?. Cancer J. 2014; 20(2):151-5. PMC: 4050065. DOI: 10.1097/PPO.0000000000000032. View

11.

Jain P, OBrien S . Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia. Expert Opin Biol Ther. 2012; 13(2):169-82. DOI: 10.1517/14712598.2012.735655. View

12.

McKeithan T . Kinetic proofreading in T-cell receptor signal transduction. Proc Natl Acad Sci U S A. 1995; 92(11):5042-6. PMC: 41844. DOI: 10.1073/pnas.92.11.5042. View

13.

Sojka D, Bruniquel D, Schwartz R, Singh N . IL-2 secretion by CD4+ T cells in vivo is rapid, transient, and influenced by TCR-specific competition. J Immunol. 2004; 172(10):6136-43. DOI: 10.4049/jimmunol.172.10.6136. View

14.

Medzhitov R . Origin and physiological roles of inflammation. Nature. 2008; 454(7203):428-35. DOI: 10.1038/nature07201. View

15.

Hoshi T, Zagotta W, Aldrich R . Biophysical and molecular mechanisms of Shaker potassium channel inactivation. Science. 1990; 250(4980):533-8. DOI: 10.1126/science.2122519. View

16.

Sansonetti P . War and peace at mucosal surfaces. Nat Rev Immunol. 2004; 4(12):953-64. DOI: 10.1038/nri1499. View

17.

Pradeu T, Carosella E . On the definition of a criterion of immunogenicity. Proc Natl Acad Sci U S A. 2006; 103(47):17858-61. PMC: 1693837. DOI: 10.1073/pnas.0608683103. View

18.

Wang S, Fouquet S, Chapon M, Salmon H, Regnier F, Labroquere K . Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PLoS One. 2011; 6(3):e17621. PMC: 3049782. DOI: 10.1371/journal.pone.0017621. View

19.

Eberl G . A new vision of immunity: homeostasis of the superorganism. Mucosal Immunol. 2010; 3(5):450-60. DOI: 10.1038/mi.2010.20. View

20.

Russell S, Peng K, Bell J . Oncolytic virotherapy. Nat Biotechnol. 2012; 30(7):658-70. PMC: 3888062. DOI: 10.1038/nbt.2287. View